Is There Life Left In Laquinimod? Teva Bows Out, But Active Biotech Interested In Brain Atrophy
Executive Summary
The extensively evaluated immunomodulator candidate laquinimod may still have potential in the treatment of neurodegenerative diseases, says Sweden's Active Biotech, despite previous disappointing clinical trials in multiple sclerosis and Huntington's disease conducted by Teva.
You may also be interested in...
Deal Watch: Mylan Clears Up Mystery, Acquires TOBI Cystic Fibrosis Products From Novartis
Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.
Pipeline Watch: Phase III Studies of CSL112 And RT-100 Imminent
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.